Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.

Portal hypertension, the most important complication with cirrhosis of the liver, is a serious disease. Sorafenib, a tyrosine kinase inhibitor is validated in advanced hepatocellular carcinoma. Because angiogenesis is a pathological hallmark of portal hypertension, the goal of our study was to deter...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Romain Coriat, Hervé Gouya, Olivier Mir, Stanislas Ropert, Olivier Vignaux, Stanislas Chaussade, Philippe Sogni, Stanislas Pol, Benoit Blanchet, Paul Legmann, François Goldwasser
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2011
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e825f27aca244bd4af209b233c81e4e9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e825f27aca244bd4af209b233c81e4e9
record_format	dspace
spelling	oai:doaj.org-article:e825f27aca244bd4af209b233c81e4e92021-11-18T06:58:50ZReversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.1932-620310.1371/journal.pone.0016978https://doaj.org/article/e825f27aca244bd4af209b233c81e4e92011-02-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21340026/?tool=EBIhttps://doaj.org/toc/1932-6203Portal hypertension, the most important complication with cirrhosis of the liver, is a serious disease. Sorafenib, a tyrosine kinase inhibitor is validated in advanced hepatocellular carcinoma. Because angiogenesis is a pathological hallmark of portal hypertension, the goal of our study was to determine the effect of sorafenib on portal venous flow and portosystemic collateral circulation in patients receiving sorafenib therapy for advanced hepatocellular carcinoma. Porto-collateral circulations were evaluated using a magnetic resonance technique prior sorafenib therapy, and at day 30. All patients under sorafenib therapy had a decrease in portal venous flow of at least 36%. In contrast, no specific change was observed in the azygos vein or the abdominal aorta. No portal venous flow modification was observed in the control group. Sorafenib is the first anti-angiogenic therapy to demonstrate a beneficial and reversible decrease of portal venous flow among cirrhotic patients.Romain CoriatHervé GouyaOlivier MirStanislas RopertOlivier VignauxStanislas ChaussadePhilippe SogniStanislas PolBenoit BlanchetPaul LegmannFrançois GoldwasserPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 6, Iss 2, p e16978 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Romain Coriat Hervé Gouya Olivier Mir Stanislas Ropert Olivier Vignaux Stanislas Chaussade Philippe Sogni Stanislas Pol Benoit Blanchet Paul Legmann François Goldwasser Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.
description	Portal hypertension, the most important complication with cirrhosis of the liver, is a serious disease. Sorafenib, a tyrosine kinase inhibitor is validated in advanced hepatocellular carcinoma. Because angiogenesis is a pathological hallmark of portal hypertension, the goal of our study was to determine the effect of sorafenib on portal venous flow and portosystemic collateral circulation in patients receiving sorafenib therapy for advanced hepatocellular carcinoma. Porto-collateral circulations were evaluated using a magnetic resonance technique prior sorafenib therapy, and at day 30. All patients under sorafenib therapy had a decrease in portal venous flow of at least 36%. In contrast, no specific change was observed in the azygos vein or the abdominal aorta. No portal venous flow modification was observed in the control group. Sorafenib is the first anti-angiogenic therapy to demonstrate a beneficial and reversible decrease of portal venous flow among cirrhotic patients.
format	article
author	Romain Coriat Hervé Gouya Olivier Mir Stanislas Ropert Olivier Vignaux Stanislas Chaussade Philippe Sogni Stanislas Pol Benoit Blanchet Paul Legmann François Goldwasser
author_facet	Romain Coriat Hervé Gouya Olivier Mir Stanislas Ropert Olivier Vignaux Stanislas Chaussade Philippe Sogni Stanislas Pol Benoit Blanchet Paul Legmann François Goldwasser
author_sort	Romain Coriat
title	Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.
title_short	Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.
title_full	Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.
title_fullStr	Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.
title_full_unstemmed	Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.
title_sort	reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.
publisher	Public Library of Science (PLoS)
publishDate	2011
url	https://doaj.org/article/e825f27aca244bd4af209b233c81e4e9
work_keys_str_mv	AT romaincoriat reversibledecreaseofportalvenousflowincirrhoticpatientsapositivesideeffectofsorafenib AT hervegouya reversibledecreaseofportalvenousflowincirrhoticpatientsapositivesideeffectofsorafenib AT oliviermir reversibledecreaseofportalvenousflowincirrhoticpatientsapositivesideeffectofsorafenib AT stanislasropert reversibledecreaseofportalvenousflowincirrhoticpatientsapositivesideeffectofsorafenib AT oliviervignaux reversibledecreaseofportalvenousflowincirrhoticpatientsapositivesideeffectofsorafenib AT stanislaschaussade reversibledecreaseofportalvenousflowincirrhoticpatientsapositivesideeffectofsorafenib AT philippesogni reversibledecreaseofportalvenousflowincirrhoticpatientsapositivesideeffectofsorafenib AT stanislaspol reversibledecreaseofportalvenousflowincirrhoticpatientsapositivesideeffectofsorafenib AT benoitblanchet reversibledecreaseofportalvenousflowincirrhoticpatientsapositivesideeffectofsorafenib AT paullegmann reversibledecreaseofportalvenousflowincirrhoticpatientsapositivesideeffectofsorafenib AT francoisgoldwasser reversibledecreaseofportalvenousflowincirrhoticpatientsapositivesideeffectofsorafenib
_version_	1718424140602408960

Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.

Ejemplares similares